- Recruiting
NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM
Updated: Sep 24, 2022
DETER-SMM
EAA173
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Sponsor
Collaborator
ClinicalTrials.gov Identifier: NCT03937635
Official Title: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
First Posted : May 6, 2019
Click here for details on ClinicalTrials.gov
Biological: Daratumumab
Drug: Dexamethasone
Drug: Lenalidomide
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
- Connecticut: Yale University New Haven
- Georgia: Emory University Atlanta
- Minnesota: Mayo Clinic Rochester Minnesota
- Texas: The University of Texas MD Anderson Cancer Center Houston
Locations
United States, Alaska
United States, Arizona
United States, Arkansas
United States, California
United States, Colorado
United States, Connecticut
United States, Florida
United States, Georgia
United States, Idaho
United States, Illinois
United States, Indiana
United States, Iowa
United States, Kansas
United States, Kentucky
United States, Louisiana
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, Missouri
United States, Montana
United States, Nebraska
United States, Nevada
United States, New Jersey
United States, New York
United States, North Carolina
United States, North Dakota
United States, Ohio
United States, Oklahoma
United States, Oregon
United States, Pennsylvania
United States, Rhode Island
United States, South Carolina
United States, South Dakota
United States, Texas
United States, Utah
United States, Virginia
United States, Washington
United States, West Virginia
United States, Wisconsin
United States, Wyoming
ECOG Trials - Currently Recruiting
NCT04566328: Phase 3 - EAA181 / EQUATE - Testing the Use of Combination Therapy in NDMM
NCT03937635: Phase 3 - EAA173 / DETER-SMM - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma
NCT03941860: Phase 3 - EAA171 / OPTIMUM - Addition of Ixazomib to Lenalidomide in Patients With Residual Myeloma
NCT02465060: Phase 2 - EAY131 / NCI-MATCH - Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)